180 LIFE SCIENCES CORP logo

ATNF

180 LIFE SCIENCES CORP

$0.41

Earnings Summary

Revenue
$0Mn
Net Profits
$18.3Mn
Net Profit Margins
+Inf%

Highlights

Revenue:

180 LIFE SCIENCES CORP’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2021. On a quarterly growth basis, 180 LIFE SCIENCES CORP has generated NaN% jump in its revenue since last 3-months.

Net Profits:

180 LIFE SCIENCES CORP’s net profit jumped 646.28% since last year same period to $18.3Mn in the Q3 2021. On a quarterly growth basis, 180 LIFE SCIENCES CORP has generated 1072.76% jump in its net profits since last 3-months.

Net Profit Margins:

180 LIFE SCIENCES CORP’s net profit margin jumped NaN% since last year same period to +Inf% in the Q3 2021. On a quarterly growth basis, 180 LIFE SCIENCES CORP has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the 180 LIFE SCIENCES CORP post its latest quarter earnings

EPS Estimate Current Quarter
-0.14
EPS Estimate Current Year
-0.14

Highlights

EPS Estimate Current Quarter:

180 LIFE SCIENCES CORP’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

180 LIFE SCIENCES CORP’s earning per share (EPS) estimates for the current year stand at -0.14.

Key Ratios

Key ratios of the 180 LIFE SCIENCES CORP post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

180 LIFE SCIENCES CORP’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2022. This indicates that the 180 LIFE SCIENCES CORP has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-03-01
-0.14
0
100%
2022-08-09
-0.13
0.09
169.23%
2022-11-10
-0.14
0
100%
2022-05-16
-0.13
0.05
138.46%

Company Information

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world's biggest drivers of disease - inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company's primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.

Organisation
180 LIFE SCIENCES CORP
Headquarters
Building 4, Palo Alto, CA, United States, 94306
Employees
0
Industry
Finance

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*